CVS (CVS) director Anne Finucane receives 1,544 deferred stock units as board retainer

Filing Impact

(Moderate)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

CVS Health Corp director Anne A. Finucane reported receiving a grant of 1,544.0041 Deferred Stock Units as compensation. These units represent the deferral of a semi-annual director retainer, valued at a reference price of $97.15 per unit under CVS’s 2017 Incentive Compensation Plan.

Each deferred stock unit is designed to convert into one share of CVS common stock and be issued in the future, based on the director’s election. Following this award, Finucane holds a total of 18,355.0364 deferred stock units, reflecting her accumulated deferred board compensation.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Finucane Anne A.

Role null

Type	Security	Shares	Price	Value
Grant/Award	Deferred Stock Units	1,544.004	$97.15	$150K

Holdings After Transaction: Deferred Stock Units — 18,355.036 shares (Direct, null)

Footnotes (1)

Consists of deferred stock units issued for deferral of a semi-annual retainer in connection with the Issuer's non-employee director compensation policy, valued at the market price, pursuant to the Issuer's 2017 Incentive Compensation Plan. Consists of deferred stock units, each to be converted into one share of common stock and issued in the future, as elected by the Reporting Person.

Key Figures

Deferred stock units granted: 1,544.0041 units Reference value per unit: $97.15 per unit Deferred units after transaction: 18,355.0364 units +2 more

5 metrics

Deferred stock units granted 1,544.0041 units Grant/award acquisition on May 14, 2026 for director retainer deferral

Reference value per unit $97.15 per unit Valuation used for semi-annual retainer deferral into stock units

Deferred units after transaction 18,355.0364 units Total deferred stock units held following the reported award

Conversion ratio 1 unit : 1 share Each deferred stock unit converts into one share of common stock

Transaction code A (Grant, award, or other acquisition) Indicates compensation-related acquisition rather than market purchase

Key Terms

Deferred Stock Units, non-employee director compensation policy, 2017 Incentive Compensation Plan, converted into one share of common stock

4 terms

Deferred Stock Units financial

"Consists of deferred stock units issued for deferral of a semi-annual retainer"

Deferred stock units are promises from a company to give an employee shares of stock at a future date, often after certain conditions are met or after leaving the company. They function like a form of delayed compensation, allowing employees to earn shares over time. For investors, they represent potential future ownership in the company, but do not provide immediate voting rights or dividends until the shares are actually received.

non-employee director compensation policy financial

"in connection with the Issuer's non-employee director compensation policy"

2017 Incentive Compensation Plan financial

"pursuant to the Issuer's 2017 Incentive Compensation Plan"

Form 4 Insider Transactions: What Each Field Means →

05/15/2026 - 05:08 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Finucane Anne A.

(Last)

(First)

(Middle)

ONE CVS DRIVE

(Street)

WOONSOCKET

RHODE ISLAND

02895

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
CVS HEALTH Corp [ CVS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/14/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Deferred Stock Units	$0	05/14/2026		A⁽¹⁾		1,544.0041		⁽²⁾	⁽²⁾	Common Stock	1,544.0041	$97.15	18,355.0364	D

Explanation of Responses:

1. Consists of deferred stock units issued for deferral of a semi-annual retainer in connection with the Issuer's non-employee director compensation policy, valued at the market price, pursuant to the Issuer's 2017 Incentive Compensation Plan.

2. Consists of deferred stock units, each to be converted into one share of common stock and issued in the future, as elected by the Reporting Person.

	/s/ Anne M. Finucane	05/15/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What did CVS (CVS) director Anne Finucane report in this Form 4?

Anne A. Finucane reported receiving 1,544.0041 Deferred Stock Units as compensation. The grant reflects deferral of a semi-annual director retainer under CVS’s 2017 Incentive Compensation Plan, rather than an open-market stock purchase or sale.

How are the deferred stock units for CVS (CVS) director compensation valued?

The deferred stock units were valued at a reference price of $97.15 per unit. This value is used to convert the director’s semi-annual retainer into units under CVS’s 2017 Incentive Compensation Plan, aligning compensation with the company’s share price.

How many CVS (CVS) deferred stock units does Anne Finucane hold after this grant?

After this grant, Anne A. Finucane holds 18,355.0364 deferred stock units. This total reflects accumulated non-employee director compensation that has been deferred into stock units rather than paid in cash, to be settled in shares later.

Will CVS (CVS) deferred stock units reported by Anne Finucane convert into common stock?

Yes. Each deferred stock unit is structured to convert into one share of CVS common stock. The shares will be issued in the future according to the timing elected by the director, as part of CVS’s non-employee director compensation program.

Is Anne Finucane’s CVS (CVS) Form 4 a market transaction?

No. The Form 4 reflects a grant of deferred stock units tied to board retainer deferral, not open-market buying or selling. It is a routine compensation-related acquisition under CVS’s 2017 Incentive Compensation Plan for non-employee directors.